Stockreport

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

Corcept Therapeutics Incorporated  (CORT) 
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors
PDF Revenue of $182.5 million, a 48 percent increase over the same period in 2023Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 millionNet income [Read more]